加味逍遥散治疗肠易激综合征的系统评价

目的:系统评价加味逍遥散治疗肠易激综合征(IBS)的疗效与安全性。方法:计算机检索VIP,CNKI,万方,CBMdisc,收集以加味逍遥散为干预措施治疗肠易激综合征的随机对照试验,按Cochrane系统评价方法,评价纳入研究的方法学质量并提取有效数据进行Meta分析。结果:共纳入17个随机对照试验,包括1 542例肠易激综合征患者。Meta分析结果显示,加味逍遥散改善IBS症状及体征的总有效率优于其他治疗方法,且复发率低于对照组,比较结果显示RR(95%CI)分别为1.31(1.24,1.38),P0.000 01],0.33(0.22,0.49),P0.000 01],缺乏对加味逍遥散不良反应及长期副作用的报告。结论:这篇系统评价显示加味逍遥散对肠易激综合征的疗效优于其他治疗方法,但由于纳入文献质量不高,存在较大的偏倚风险,缺乏随访或随访资料不完善,不能评价加味逍遥散的远期疗效和安全性,使其对肠易激综合征临床治疗的指导意义受到限制。

Evaluate of Jiawei Xiaoyao San for Irritable Bowel Syndrome

Objective: The aim of this study was to evaluate the efficacy and safety of Jiawei Xiaoyao San for irritable bowel syndrome. Method: We searched the VIP, CNKI, Wanfang and China biology medicine disc(CBMdisc) databases. Randomized controlled trials of clinical therapeutic studies on Jiawei Xiaoyao San for irritable bowel syndrome were included. The quality of included studies was evaluated and Meta-analysis was performed. Result: In this study, 17 trials involving 1 542 patients were included. Meta-analysis indicated that Jiawei Xiaoyao San was lower in the recurrence rate and more effective than other drugs in improving symptoms and signs of irritable bowel syndrome. The RR value (95%CI)wereRR=0.33,95%CI(0.22,0.49), P <0.000 01]andRR=1.31,95%CI(1.24,1.38), P< 0.000 01], respectively. The most included researches did not report adverse reactions. Conclusion: Based on this review, Jiawei Xiaoyao San is effective for irritable bowel syndrome. However, the evidence is not strong enough due to the low quality of included trials. Further, large-sample and multi-center studies are needed.